Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 1
1993 1
1994 1
1995 3
1996 10
1997 8
1998 20
1999 17
2000 18
2001 19
2002 16
2003 22
2004 22
2005 15
2006 12
2007 19
2008 24
2009 17
2010 14
2011 8
2012 12
2013 12
2014 12
2015 14
2016 15
2017 12
2018 15
2019 9
2020 12
2021 5
Text availability
Article attribute
Article type
Publication date

Search Results

368 results
Results by year
Filters applied: . Clear all
Page 1
Comparative Effectiveness of First-Line Medications for Primary Open-Angle Glaucoma: A Systematic Review and Network Meta-analysis.
Li T, Lindsley K, Rouse B, Hong H, Shi Q, Friedman DS, Wormald R, Dickersin K. Li T, et al. Ophthalmology. 2016 Jan;123(1):129-40. doi: 10.1016/j.ophtha.2015.09.005. Epub 2015 Oct 31. Ophthalmology. 2016. PMID: 26526633 Free PMC article. Review.
The mean reductions (95% credible intervals) in IOP in millimeters of mercury at 3 months ordered from the most to least effective drugs were as follows: bimatoprost 5.61 (4.94; 6.29), latanoprost 4.85 (4.24; 5.46), travoprost 4.83 (4.12; 5.54), levobunolol 4.51 (3.85; 5.24), taf …
The mean reductions (95% credible intervals) in IOP in millimeters of mercury at 3 months ordered from the most to least effective drugs wer …
Drugs for common eye disorders.
[No authors listed] [No authors listed] Med Lett Drugs Ther. 2019 Dec 2;61(1586):187-194. Med Lett Drugs Ther. 2019. PMID: 31770361 Review. No abstract available.
Treatment of cystoid macular edema secondary to retinitis pigmentosa: a systematic review.
Bakthavatchalam M, Lai FHP, Rong SS, Ng DS, Brelen ME. Bakthavatchalam M, et al. Surv Ophthalmol. 2018 May-Jun;63(3):329-339. doi: 10.1016/j.survophthal.2017.09.009. Epub 2017 Oct 5. Surv Ophthalmol. 2018. PMID: 28987613 Review.
Oral acetazolamide has the strongest clinical basis for treatment and was superior to topical dorzolamide. Rebound of CME was commonly seen in the long term, regardless of the choice of treatment. Oral acetazolamide should be the first-line treatment in CME secondary to re …
Oral acetazolamide has the strongest clinical basis for treatment and was superior to topical dorzolamide. Rebound of CME was commonl …
The Carbonic Anhydrase Inhibitor Dorzolamide Stimulates the Differentiation of Human Meibomian Gland Epithelial Cells.
Han X, Yang S, Kam WR, Sullivan DA, Liu Y. Han X, et al. Curr Eye Res. 2020 Dec;45(12):1604-1610. doi: 10.1080/02713683.2020.1772832. Epub 2020 May 31. Curr Eye Res. 2020. PMID: 32434386
PURPOSE: Clinical studies have indicated that the long-term use of topical antiglaucoma drugs, such as carbonic anhydrase inhibitors (CAIs), may lead to meibomian gland dysfunction (MGD). We hypothesize that these adverse effects involve a direct influence on human …
PURPOSE: Clinical studies have indicated that the long-term use of topical antiglaucoma drugs, such as carbonic anhydrase inhibitors (CAIs), …
Clinical pharmacokinetics of dorzolamide.
Martens-Lobenhoffer J, Banditt P. Martens-Lobenhoffer J, et al. Clin Pharmacokinet. 2002;41(3):197-205. doi: 10.2165/00003088-200241030-00004. Clin Pharmacokinet. 2002. PMID: 11929320 Review.
Dorzolamide is a carbonic anhydrase inhibitor for topical ophthalmic application. ...However, the inhibition of carbonic anhydrase in red blood cells is moderate in the course of a topical treatment, avoiding systemic adverse effects. This review summarises t
Dorzolamide is a carbonic anhydrase inhibitor for topical ophthalmic application. ...However, the inhibition of carbonic anhydrase in
Can dorzolamide/timolol-fixed combination effectively treat primary open-angle glaucoma?: A protocol for systematic review and meta-analysis.
Qi YX, Liu HW, Sun Q, Su XJ, Han L. Qi YX, et al. Medicine (Baltimore). 2020 Nov 20;99(47):e23245. doi: 10.1097/MD.0000000000023245. Medicine (Baltimore). 2020. PMID: 33217844 Free PMC article.
BACKGROUND: Primary open-angle glaucoma (POAG) is a very common disorder, and it is the second leading cause that results in blindness worldwide after cataracts. Previous studies have reported that dorzolamide/timolol-fixed combination (DTFC) can be used in treating POAG. …
BACKGROUND: Primary open-angle glaucoma (POAG) is a very common disorder, and it is the second leading cause that results in blindness world …
Efficacy and safety of brimonidine and dorzolamide for intraocular pressure lowering in glaucoma and ocular hypertension.
Katz LJ, Simmons ST, Craven ER. Katz LJ, et al. Curr Med Res Opin. 2007 Dec;23(12):2971-83. doi: 10.1185/030079907X242476. Curr Med Res Opin. 2007. PMID: 17949534 Review.
Six other trials showed similar efficacy, and one additional monotherapy study showed lower IOP with dorzolamide treatment. Ocular burning was noted with dorzolamide more than any other adverse event with either drug. ...In certain patients with glaucoma and …
Six other trials showed similar efficacy, and one additional monotherapy study showed lower IOP with dorzolamide treatment. Ocular bu …
Dorzolamide, a 40-year wait. From an oral to a topical carbonic anhydrase inhibitor for the treatment of glaucoma.
Ponticello GS, Sugrue MF, Plazonnet B, Durand-Cavagna G. Ponticello GS, et al. Pharm Biotechnol. 1998;11:555-74. Pharm Biotechnol. 1998. PMID: 9760696 Review.
Dorzolamide, on the basis of its pharmacological profile and lack of undesirable side effects in safety assessment studies together with the fact that it could be formulated in solution at 2%, underwent extensive clinical studies. ...Tachyphylaxis did not develop to
Dorzolamide, on the basis of its pharmacological profile and lack of undesirable side effects in safety assessment studies tog
Topical dorzolamide 2%/timolol 0.5%: a review of its use in the treatment of open-angle glaucoma.
Ormrod D, McClellan K. Ormrod D, et al. Drugs Aging. 2000 Dec;17(6):477-96. doi: 10.2165/00002512-200017060-00005. Drugs Aging. 2000. PMID: 11200308 Review.
This non-blind patient-preference study found that both regimens reduced IOP. However, the dorzolamide/timolol combination was preferred by the patients because of reduced frequency and severity of adverse effects and less frequent administration. Dorzolam
This non-blind patient-preference study found that both regimens reduced IOP. However, the dorzolamide/timolol combination was prefer …
Preventive Dorzolamide-Timolol for Rising Intraocular Pressure During Steep Trendelenburg Position Surgery.
Molloy BL, Cong X, Watson C. Molloy BL, et al. AANA J. 2016 Jun;84(3):189-96. AANA J. 2016. PMID: 27501654 Clinical Trial.
The generalized estimating equations model was used to analyze treatment and time effects and treatment by time interactions. Ninety patients were recruited, with 46 receiving dorzolamide-timolol treatment and 44 receiving balanced salt solution. ...Treatment eff
The generalized estimating equations model was used to analyze treatment and time effects and treatment by time interactions. Ninety …
368 results